We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

216 hedge funds and large institutions have $3.86B invested in Amicus Therapeutics in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 82 increasing their positions, 73 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $11.5M | Put options by funds: $4.95M

17% more capital invested

Capital invested by funds: $3.3B → $3.86B (+$557M)

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

12% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 73

2.67% more ownership

Funds ownership: 105.31%107.98% (+2.7%)

4% less funds holding

Funds holding: 226216 (-10)

22% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 32

Holders
216
Holders Change
-10
Holders Change %
-4.42%
% of All Funds
3.39%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.11%
New
25
Increased
82
Reduced
73
Closed
32
Calls
$11.5M
Puts
$4.95M
Net Calls
+$6.55M
Net Calls Change
+$8.49M
Name Holding Trade Value Shares
Change
Change in
Stake
RJA
151
Raymond James & Associates
Florida
$302K +$286K +24,080 New
SCM
152
SevenOneSeven Capital Management
Pennsylvania
$300K -$2K -169 -0.8%
AIP
153
Ameritas Investment Partners
Nebraska
$291K +$18.2K +1,535 +7%
IWC
154
Integrated Wealth Concepts
Massachusetts
$284K +$269K +22,645 New
Mitsubishi UFJ Asset Management
155
Mitsubishi UFJ Asset Management
Japan
$275K -$46.5K -3,922 -15%
XT
156
XTX Topco
Cayman Islands
$269K +$254K +21,416 New
SOS
157
Silver Oak Securities
Tennessee
$260K +$39.3K +3,313 +19%
NC
158
NinePointTwo Capital
California
$251K
CIM
159
CIM Investment Management
Pennsylvania
$248K
Squarepoint
160
Squarepoint
New York
$218K +$59.2K +4,986 +40%
NSEDCP
161
NJ State Employees Deferred Compensation Plan
New Jersey
$214K
X
162
Xponance
Pennsylvania
$207K +$5.47K +461 +3%
GAM
163
Gotham Asset Management
New York
$204K -$240K -20,242 -55%
VPIM
164
Vanguard Personalized Indexing Management
California
$194K +$20.4K +1,716 +12%
Osaic Holdings
165
Osaic Holdings
Arizona
$193K -$2.38K -201 -1%
MLICM
166
Metropolitan Life Insurance Company (MetLife)
New York
$190K +$4.2K +354 +2%
Creative Planning
167
Creative Planning
Kansas
$176K +$166K +14,013 New
AIMCA
168
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$170K +$161K +13,544 New
SOW
169
State of Wyoming
Wyoming
$164K +$99.7K +8,404 +181%
TRCT
170
Tower Research Capital (TRC)
New York
$158K -$81.2K -6,839 -35%
JMPWA
171
JP Morgan Private Wealth Advisors
California
$155K +$12.9K +1,084 +10%
OSAM
172
O'Shaughnessy Asset Management
Connecticut
$153K -$653 -55 -0.5%
FB
173
Fulton Bank
Pennsylvania
$144K -$4.54K -383 -3%
CA
174
Calton & Associates
Florida
$137K -$5.23K -441 -4%
GPA
175
Guerra Pan Advisors
New Jersey
$134K

FOLD Hedge Fund Activity: Q2 2023 in Review

216 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2023, worth a combined $3.86B — up 17% from $3.3B a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of FOLD and 25 opened new positions — a net loss of 7 holders — while 73 trimmed existing stakes and 82 added.

The largest buyer was Deutsche Bank, adding an estimated $61.1M. The largest seller was Morgan Stanley, cutting an estimated $40.8M.

  • 216 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2023, down from 226 in Q1 2023.
  • Funds reported $3.86B of Amicus Therapeutics stock for Q2 2023, up 17% quarter-over-quarter.
  • 25 funds opened new Amicus Therapeutics positions in Q2 2023 and 32 closed out, a net change of -7 holders.
  • The largest Amicus Therapeutics buyer in Q2 2023 was Deutsche Bank, an estimated $61.1M added.
  • The largest Amicus Therapeutics seller in Q2 2023 was Morgan Stanley, an estimated $40.8M sold.

Based on aggregated 13F filings for Q2 2023.